Company Overview and News

 
Analyst corner: ‘Buy’on Hero MotoCorp; FY19/20 EPS cut by 4/7%

20h financialexpress
In 2QFY19, Hero Motocorp (HMCL) reported an EBITDA margin of 15.2%, lower by 40bps QoQ, owing to higher other expenses. As two-wheeler demand was muted during 2QFY19 due to increase in fuel price and insurance premium, all eyes are on the response to the festive sales. The management indicated that the first few festive days have witnessed flat growth YoY, but sales are gradually picking pace. Recent hike in MSPs will boost rural sales.
500182 HEROMOTOCO HRTQY

5
Sensex logs first fall in 4 days, tanks 383 pts on rupee woes

2018-10-17 freepressjournal.in
Mumbai: The BSE benchmark Sensex snapped its three-day gains, plunging 383 points due to heavy selling mainly in financial and auto stocks as rising crude prices and rupee volatility spooked investors. The flagship index swung nearly 880 points both ways on alternate bouts of buying and selling during the session. The NSE Nifty too fell by 131.70 points to slip below 10,500-mark. Intense selling pressure was witnessed in select counters led by auto, realty and oil&gas stocks.
BAJAJ-AUTO 500325 RELIANCE 532977 BHRQY 533278 532215 535789 500470 532187 AXISBANK RIGD HDFCBANK HEROMOTOCO 500570 BHARTIARTL TATAMOTORS CLNDY RLNIY YESBANK AXB INDUSINDBK 511072 IBN IDKQY 535322 532648 YYBKY VEDL REPCOHOME AXBKY 500182 IBULHSGFIN 532454 AXBA DHFL ICICIBANK TTST TATASTEEL TATLY HDB 532174 500180 HRTQY COALINDIA TTM

 
Hero MotoCorp hits 2-week high

2018-10-17 thehindubusinessline
Profit fell to Rs 976 crore from Rs 1,010 crore a year earlier, but still came in above analysts' expectation of Rs 938 crore.
500182 DB HEROMOTOCO HRTQY

 
Hero MotoCorp Q2: Costs apply brakes on profit growth

2018-10-17 livemint
Mounting cost pressures are showing up in slipping profitability at Hero MotoCorp Ltd, explaining why investors are pessimistic. Shares of the two-wheeler maker have declined by almost 18% in this fiscal year so far, underperforming both the BSE Auto and the BSE 100 indices.
500182 HEROMOTOCO HRTQY

5
Forbes list: This Indian company is among world’s 25 best employers; find out who leads rankings

2018-10-17 financialexpress
Forbes’ global 2000 best employers list: Larsen & Toubro, a leading player in country’s engineering and construction sector, has featured at 22nd rank among the top 25 companies in the Forbes’ global 2000 best employers list. The chart is topped by Google parent Alphabet. Other than L&T, the only other Indian firms to feature in the top 100 list are Mahindra & Mahindra at 55, Grasim Industries at 59 and HDFC at 91.
GRASIM BAJAJ-AUTO PWQFY IOB 500820 500228 TCHQY 532977 532755 ASIANPAINT 532810 532215 532388 AXISBANK HDFCBANK HEROMOTOCO 500570 TATAMOTORS SBAZ GRSJY AXB KMBKY IBN JSWSTEEL TECHM AXBKY 500182 PFC GRSXY AXBA ICICIBANK HDB 532174 500180 KOTAKBANK 500300 HRTQY 500247 TTM

 
Hero Moto trades marginally higher post Q2 results

2018-10-17 moneycontrol
Shares of two-wheeler major Hero Motocorp are trading marginally higher in the early trade on Wednesday on the back of subdued second quarter numbers declared by the company on September 16.
500182 HEROMOTOCO HRTQY

 
An evening walk down Dalal Street | Indices snap 3-day winning streak, Nifty ends around 10,450; midcaps crack

2018-10-17 moneycontrol
A huge reversal in trend played on the market today as weakness in financials weighed big on Sensex and the Nifty. The 50-share index, which rose above 10,700 in the opening tick, ended the day just above 10,450.
NIITTECH 500182 532541 MARUTI BIRLAMONEY HEROMOTOCO HRTQY MRZUY 532974 532500

 
A not-so-smooth ride for Hero MotoCorp

2018-10-16 thehindubusinessline
Hero’s market share in entry bikes, for the first half of this fiscal, slipped to 72.6 per cent against 74.2 per cent registered in the same period last year - S_Subramanium
BAJAJ-AUTO 500182 HEROMOTOCO 532977 HRTQY

 
Hero MotoCorp Q2 PAT down at ₹976 cr

2018-10-16 thehindubusinessline
Country’s largest two-wheeler manufacturer Hero MotoCorp on Tuesday reported a net income of ₹976 crore for the second quarter ended September 30 — down 3 per cent as compared with ₹1,010 crore in the corresponding period last year.
500182 HEROMOTOCO HRTQY

5
Podcast | Editor#39;s pick of the day - It#39;s raining deals this festive season

2018-10-16 moneycontrol - 1
Everything comes at a price. But during this one rather extended period of time of the year, there is a discount to that price. Nothing, of course, is free.
BAJAJ-AUTO 500182 MARUTI HEROMOTOCO 532977 HRTQY 500570 TATAMOTORS MRZUY TTM 532500

 
Hero MotoCorp Limited - Outcome of Board Meeting

2018-10-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500182 HEROMOTOCO HRTQY

 
Sensex rises 300 points on earnings optimism

2018-10-16 freepressjournal.in
Mumbai: The BSE Sensex on Tuesday surged 297 points to went past the key 35,000-level, continuing its winning-run for the third straight day amid optimism ahead of quarterly earnings from heavyweights and recovery in the rupee. Meanwhile, the rupee strengthened by 25 paise to 73.58 (intra-day) against the US dollar in the forex market. Besides, easing global crude prices and positive cues from Asian markets and a higher opening in european shares too fuelled the rally.
500182 HEROMOTOCO HRTQY

 
Hero Motocorp Q2 profit falls 3% to ₹976 crore

2018-10-16 livemint
Bengaluru: Hero MotoCorp Ltd, the world’s largest two-wheeler maker, posted a 3.4% drop in quarterly profit on Tuesday, hurt by higher expenses amid a depreciating rupee.
500182 HEROMOTOCO HRTQY

 
Hero MotoCorp Limited - Appointment

2018-10-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500182 HEROMOTOCO HRTQY

 
Hero MotoCorp Limited - Press Release

2018-10-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500182 HEROMOTOCO HRTQY

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...